<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370266</url>
  </required_header>
  <id_info>
    <org_study_id>8247</org_study_id>
    <nct_id>NCT00370266</nct_id>
  </id_info>
  <brief_title>Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intraocular injection of triamcinolone is&#xD;
      effective in the treatment of macular edema in acute branch retinal vein occlusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal triamcinolone has recently been shown to have beneficial effect on chronic&#xD;
      macular edema due to vein occlusion and preventive effect on neovascularization.&#xD;
      Hypothetically, prevention of macular derangement by reducing the amount of edema from early&#xD;
      phase after occlusion until restoration of collaterals seems to be helpful in these eyes. To&#xD;
      our knowledge, no prospective randomized clinical trial, considering both macular changes and&#xD;
      preventive effect on neovascularization has been published for intravitreal triamcinolone in&#xD;
      acute branch retinal vein occlusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central macular thickness</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal neovascularization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cataract progression</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eyes suffering from branch retinal vein occlusion with less than 2 months duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Monocularity,&#xD;
&#xD;
          -  Previous intraocular surgery or laser therapy&#xD;
&#xD;
          -  Glaucoma or ocular hypertension&#xD;
&#xD;
          -  Significant media opacity&#xD;
&#xD;
          -  Existence of traction on the macula&#xD;
&#xD;
          -  Visual acuity â‰¥20/40&#xD;
&#xD;
          -  Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alireza Ramezani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alireza Ramezani, MD</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <keyword>Macular edema</keyword>
  <keyword>Branch retinal vein occlusion</keyword>
  <keyword>Intravitreal triamcinolone</keyword>
  <keyword>Macular thickness</keyword>
  <keyword>Retinal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

